Alkermes plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALKS Nasdaq 2836 www.alkermes.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alkermes plc

Alkermes to Report Third Quarter Financial Results on November 3, 2026 - Oct 20th, 2026 2:00 pm
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline - Oct 20th, 2026 7:00 am
Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst calls - Oct 16th, 2026 7:38 am
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? - Oct 16th, 2026 5:12 am
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research - Oct 13th, 2026 5:00 am
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Oct 9th, 2026 7:28 am
Alkermes (ALKS) Holds To Its Narrative, Is The Pullback A Buying Opportunity? - Oct 9th, 2026 3:13 am
Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS) - Oct 5th, 2026 7:48 am
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? - Sep 30th, 2026 10:47 am
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works? - Sep 25th, 2026 9:59 pm
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290 - Sep 23rd, 2026 5:13 am
Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says - Sep 22nd, 2026 9:39 am
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Sep 22nd, 2026 9:15 am
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide - Sep 22nd, 2026 8:17 am
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won - Sep 21st, 2026 2:15 pm
Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290 - Sep 21st, 2026 6:41 am
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) - Sep 21st, 2026 5:00 am
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors - Sep 16th, 2026 5:00 am